These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2988273)

  • 1. Blood lymphocyte population 4 to 6 years after adjuvant cyclic chemotherapy for operable breast carcinoma.
    Blomgren H; Rotstein S; Petrini B; Wasserman J
    Acta Radiol Oncol; 1985; 24(2):123-7. PubMed ID: 2988273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte subpopulations and reactivity in breast cancer recurrence following adjuvant postoperative chemotherapy.
    Petrini B; Rotstein S; Blomgren H; Wasserman J; Baral E
    Anticancer Res; 1984; 4(3):151-6. PubMed ID: 6465853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of adjuvant chemotherapy on the blood lymphocyte population in operable breast carcinoma. Comparison between two types of treatments.
    Strender LE; Petrini B; Blomgren H; Wasserman J; Wallgren A; Baral E
    Acta Radiol Oncol; 1982; 21(4):217-24. PubMed ID: 6293264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adjuvant chemotherapy on specific and non-specific immune mechanisms.
    Zielinski CC; Müller C; Kubista E; Staffen A; Eibl MM
    Acta Med Austriaca; 1990; 17(1):11-4. PubMed ID: 2353562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of various immunological tests in breast cancer patients treated with adjuvant postoperative chemotherapy.
    Rotstein S; Blomgren H; Nilsson B; Petrini B; Wasserman J; Baral E
    Chemioterapia; 1984 Aug; 3(4):227-31. PubMed ID: 6549437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of blood T cell subsets in patients receiving postoperative adjuvant chemotherapy for breast cancer.
    Petrini B; Wasserman J; Blomgren H; Rotstein S
    Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1485-7. PubMed ID: 6238826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant radiation therapy compared with cyclic chemotherapy in patients with mammary carcinoma. II. Changes of mitogen responses of blood lymphocytes.
    Strender LE; Blomgren H; Wasserman J; Petrini B; Baral E
    Acta Radiol Oncol; 1981; 20(5):299-304. PubMed ID: 6278848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study.
    Wiltschke C; Krainer M; Budinsky AC; Berger A; Müller C; Zeillinger R; Speiser P; Kubista E; Eibl M; Zielinski CC
    Br J Cancer; 1995 Jun; 71(6):1292-6. PubMed ID: 7779726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant radiation therapy compared with cyclic chemotherapy in patients with mammary carcinoma. I. Changes of blood lymphocyte subpopulations.
    Petrini B; Wasserman J; Baral E; Blomgren H; Strender LE
    Acta Radiol Oncol; 1981; 20(2):137-41. PubMed ID: 6270966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of adjuvant chemotherapy in male breast cancer.
    Patel HZ; Buzdar AU; Hortobagyi GN
    Cancer; 1989 Oct; 64(8):1583-5. PubMed ID: 2676137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant CMF chemotherapy in operable breast cancer: ten years later.
    Bonadonna G; Rossi A; Valagussa P
    Lancet; 1985 Apr; 1(8435):976-7. PubMed ID: 2859425
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant CMF chemotherapy in operable breast cancer: ten years later.
    Bonadonna G; Rossi A; Valagussa P
    World J Surg; 1985 Oct; 9(5):707-13. PubMed ID: 3840626
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
    Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
    J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results.
    Colozza M; Gori S; Mosconi AM; Anastasi P; de Angelis V; Giansanti M; Mercati U; Aristei C; Latini P; Tonato M
    Am J Clin Oncol; 1996 Feb; 19(1):10-7. PubMed ID: 8554028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
    Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
    Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast carcinoma in young patients.
    Ménard S; Casalini P; Cascinelli N; Balsari A
    Lancet; 2000 Sep; 356(9235):1113. PubMed ID: 11009169
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.